The 2 most recent market catalysts affecting $OBX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32
Leerink Partners has initiated coverage on Obsidian Therapeutics (OBX) with an 'Outperform' rating and a $32 price target. This event is significant as new analyst coverage, especi…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
Piper Sandler Initiates Coverage On Obsidian Therapeutics with Overweight Rating, Announces Price Target of $42
Piper Sandler's initiation of coverage on Obsidian Therapeutics (OBX) with an 'Overweight' rating and a $42 price target is a positive development for the company. Analyst coverage…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.